mAbxience and Teva announce second strategic global license agreement for biosimilar oncology treatment candidate

mAbxience, a Fresenius Kabi majority-owned group, and Teva Pharmaceuticals International have entered a second global licensing agreement for an anti PD-1 biosimilar candidate currently in development for the treatment of multiple oncology indications. The agreement covers global markets, including in Europe and the United States.

Fresenius Kabi, an operating company of Fresenius, continues to strengthen its biopharma business and strategic network through this new agreement, which builds on the solid foundation of the initial partnership with Teva. This directly underscores the companies’ mutual goal to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care. By leveraging expertise and resources, the collaboration continues to drive innovation and accessibility in global healthcare, all in line with #FutureFresenius.